Unknown PHASE2 INTERVENTIONAL 1-arm NCT04279379

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Combination of Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study

Sponsor: Beijing Tongren Hospital

Conditions Extranodal NK/T-cell Lymphoma

Interventions Decitabine Sintilimab

Updated 6 times since 2020 Last updated: May 6, 2020 Started: Apr 1, 2020 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04279379, this PHASE2 trial focuses on Extranodal NK/T-cell Lymphoma and remains ongoing. Sponsored by Beijing Tongren Hospital, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Recruiting PHASE2
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Mar 2020 — Jun 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tongren Hospital

Data source: Beijing Tongren Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China